# Dabigatran Etexilate vs Enoxaparin in Prevention of Venous Thromboembolism (VTE) Post Total Knee Replacement

> **NCT00152971** · PHASE3 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 2615 (actual)

## Conditions studied

- Arthroplasty, Replacement, Knee
- Thromboembolism

## Interventions

- **DRUG:** Dabigatran Dose 1 - day 2 to completion
- **DRUG:** Dabigatran Dose 1 - day 1
- **DRUG:** Dabigatran Dose 2 - day 2 to completion
- **DRUG:** Dabigatran Dose 2 - day 1
- **DRUG:** Enoxaparin

## Key facts

- **NCT ID:** NCT00152971
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-11
- **Primary completion:** 2006-06
- **Final completion:** —
- **Target enrollment:** 2615 (ACTUAL)
- **Last updated:** 2014-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00152971

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00152971, "Dabigatran Etexilate vs Enoxaparin in Prevention of Venous Thromboembolism (VTE) Post Total Knee Replacement". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00152971. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*